The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER-1, an international, placebo-controlled, phase 3 study of ixekizumab in patients with moderate-to-severe psoriasis. Patients were randomized to a placebo (n = 13) or ixekizumab 80 mg every 4 (IXEQ4W, n = 12) or 2 (IXEQ2W, n = 8) weeks, from week 0-12. At week 12, ixekizumab-treated patients with a static Physician Global Assessment score 0 or 1 (sPGA [0,1]; n = 16) were re-randomized to a placebo (n = 6), ixekizumab 80 mg every 12 (IXEQ12W, n = 5) or 4 (IXEQ4W, n = 5) weeks, from week 12-60. At week 12, more ixekizumab-treated versus placebo-treated patients achieved sPGA (0,1) (≥66.7% vs 0%), ≥75% improvement in Psoriasis Area and Severity Index (≥75% vs 0%), and sPGA (0) or 100% improvement in Psoriasis Area and Severity Index (both ≥33.3% vs 0%), with improved symptoms and quality of life. At week 60, 100% (IXEQ4W), 40.0% (IXEQ12W) and 16.7% (placebo) had maintained sPGA (0,1). From week 0-12, treatment-emergent adverse events were 76.9% (placebo), 75.0% (IXEQ4W) and 87.5% (IXEQ2W), and from week 12-60 were 66.7% (placebo) and 100% (IXEQ12W, IXEQ4W). Ixekizumab-treated patients had no severe treatment-emergent adverse events, and one serious TEAE (IXEQ4W); infection was the most frequent treatment-emergent adverse event. In conclusion, ixekizumab for 60 weeks was effective and safe for Japanese patients with moderate-to-severe psoriasis, in line with the overall findings from UNCOVER-1.
INTRODUCTION
Psoriasis is a chronic, immune-mediated, skin condition characterized by red scaly plaques. 1 In Japan, 4.43% of patients (n = 67 448) attending dermatology clinics in 2007-2008 had psoriasis, 2 which was estimated to affect 0.34% of the population in 2011. 3 In international phase 3 trials, ixekizumab markedly improved the clinical signs and symptoms of moderateto-severe psoriasis. 4, 5 In a single-arm study of ixekizumab in Japanese patients (UNCOVER-J), 98.7% with moderate-tosevere psoriasis achieved ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12, 6 which was maintained up to 52 weeks with no unexpected safety signals. 7 Herein, we assess the efficacy and safety of ixekizumab for 60 weeks in Japanese patients participating in UNCOVER-1, an ongoing, placebo-controlled phase 3 study (NCT01474512; JapicCTI-121952). 4 
METHODS

Study design
Protocol approval and ethics have been described. 4 Eligible patients (aged ≥18 years) had moderate-to-severe psoriasis ≥6 months before randomization, were candidates for phototherapy and/or systemic therapy, and had body surface area involvement ≥10%, static Physician's Global Assessment (sPGA) score ≥3, and PASI score ≥12 at screening and baseline. 4 Patients were randomized (1:1:1) to receive a placebo or ixekizumab 80 mg (160 mg at week 0) every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) from week 0-12 (induction period). At week 12, ixekizumab-treated patients with sPGA (0,1) (responders) were re-randomized (1:1:1) to a placebo, ixekizumab 80 mg every 12 weeks (IXEQ12W) or IXEQ4W from week 12-60 (maintenance period 
RESULTS
Patient characteristics
At week 0, 33 Japanese patients participating in UNCOVER-1 (n = 1296) were randomized to a placebo (n = 13), IXEQ4W (n = 12) or IXEQ2W (n = 8). At week 12, 16 responders (IXEQ4W n = 8, IXEQ2W n = 8) were re-randomized to a placebo (n = 6), IXEQ12W (n = 5) or IXEQ4W (n = 5). By week 60, three placebo-treated and three IXEQ12W-treated patients had relapsed. Eight patients discontinued the study, most commonly because of adverse events (n = 5). Demographics and disease characteristics were similar among treatment groups ( Table 1 ). The mean duration of psoriasis was longer for the IXEQ4W group, and previous non-biological + biological therapy was more common in the placebo group.
Efficacy
At week 12, eight (100%) IXEQ2W-treated and eight (66.7%) IXEQ4W-treated patients achieved sPGA (0,1), and eight (100%) IXEQ2W-treated and nine (75.0%) IXEQ4W-treated patients achieved PASI 75 (Table 2) . No placebo-treated patient achieved sPGA (0,1) or PASI 75, nor sPGA (0), PASI 90 or PASI 100. Furthermore, six (75.0%) IXEQ2W-treated patients and seven (58.3%) IXEQ4W-treated patients achieved PASI 90, with at least three (37.5%) IXEQ2W-treated and four (33.3%) IXEQ4W-treated patients achieving complete resolution of psoriasis plaques (sPGA [0] or PASI 100).
Five (all) IXEQ4W-treated, two IXEQ12W-treated and one placebo-treated patient maintained sPGA (0,1) until week 60 (Table 2 ). PASI response rates were numerically greater for IXEQ4W than IXEQ12W and the placebo.
At week 12, improvements in Itch Numeric Rating Scale and Dermatology Life Quality Index scores were numerically greater for IXEQ2W than IXEQ4W, and were minimal for the placebo (Table 2) . Improvement in NAPSI scores were minimal for the placebo and IXEQ4W, but more marked for IXEQ2W.
Safety
In the Japanese subgroup, TEAE were reported by 10 placebo-treated and 16 ixekizumab-treated patients from week 0-12, and four placebo-treated and 10 (all) ixekizumab-treated patients from week 12-60; for ixekizumab-treated patients, none were considered severe (Table 3) . TEAE considered possibly drug-related were reported by nine (week 0-12) and two (week 12-60) ixekizumab-treated patients. Three IXEQ4W-treated patients discontinued because of generalized pruritus (mild severity), allergic edema (moderate severity) and bronchopneumonia (moderate severity, also considered a serious adverse event). No deaths were reported.
In ixekizumab-treated patients, infection, particularly nasopharyngitis, was the most frequently reported TEAE of special interest (Table 3 ). All infections were mild, except for moderate cases of bronchopneumonia (n = 1), nasopharyngitis (n = 2), tinea pedis (n = 1) and influenza (n = 1). Cytopenias (leukopenia and neutropenia [n = 1], leukopenia and lymphopenia [n = 1]) were mild, all allergic/hypersensitivity reactions were non-anaphylactic, and all injection-site reactions were mild and resolved within 1-3 days. One case of elevated alanine aminotransferase and aspartate aminotransferase concentrations above normal limits during the induction period resulted in study discontinuation at week 44 after re-randomization from IXEQ4W to a placebo at week 12, and two cases of mild increases in alanine aminotransferase concentrations resolved during the study. No patients had tuberculosis.
DISCUSSION
Ixekizumab effectively reduced the symptoms and signs of moderate-to-severe psoriasis in Japanese patients participating in UNCOVER-1. At week 12, high levels of psoriasis clearance (sPGA [0,1], PASI 75) were seen in ≥66.7% of ixekizumab-treated patients and were maintained through to week 60 (sPGA [0,1]), with IXEQ2W (induction) and IXEQ4W (maintenance) providing the highest response rates. Furthermore, ixekizumab improved nail psoriasis, itch severity and quality of life with an acceptable safety profile.
Efficacy findings for the 33 Japanese patients were in line with those for the overall UNCOVER-1 population. 4 Both populations achieved high levels of psoriasis clearance at week 12; in the overall population, sPGA (0,1) and PASI 75 were significantly (P < 0.001) greater for ixekizumab than the placebo, and numerically greater for IXEQ2W than IXEQ4W (Table 2) . 4 Doses of ixekizumab every 4 weeks provided the best opportunity for maintaining psoriasis clearance (sPGA [0,1]) in both populations ( Table 2 ). The low mean baseline NAPSI score of 
Patients with Adverse events were coded and summarized using the Medical Dictionary for Regulatory Activities, Version 16.1.
